Neurocrine Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $113.47
- Today's High:
- $119.28
- Open Price:
- $115.64
- 52W Low:
- $89.04
- 52W High:
- $129.29
- Prev. Close:
- $109.64
- Volume:
- 2360322
Company Statistics
- Market Cap.:
- $10.71 billion
- Book Value:
- 18.986
- Revenue TTM:
- $1.67 billion
- Operating Margin TTM:
- 17.6%
- Gross Profit TTM:
- $1.00 billion
- Profit Margin:
- 10.54%
- Return on Assets TTM:
- 7.97%
- Return on Equity TTM:
- 10.77%
Company Profile
Neurocrine Biosciences Inc had its IPO on 1996-05-23 under the ticker symbol NBIX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Neurocrine Biosciences Inc has a staff strength of 1,350 employees.
Stock update
Shares of Neurocrine Biosciences Inc opened at $115.64 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $113.47 - $119.28, and closed at $117.1.
This is a +6.8% increase from the previous day's closing price.
A total volume of 2,360,322 shares were traded at the close of the day’s session.
In the last one week, shares of Neurocrine Biosciences Inc have increased by +5.85%.
Neurocrine Biosciences Inc's Key Ratios
Neurocrine Biosciences Inc has a market cap of $10.71 billion, indicating a price to book ratio of 7.2969 and a price to sales ratio of 8.078.
In the last 12-months Neurocrine Biosciences Inc’s revenue was $1.67 billion with a gross profit of $1.00 billion and an EBITDA of $313 million. The EBITDA ratio measures Neurocrine Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neurocrine Biosciences Inc’s operating margin was 17.6% while its return on assets stood at 7.97% with a return of equity of 10.77%.
In Q2, Neurocrine Biosciences Inc’s quarterly earnings growth was a positive 200% while revenue growth was a positive 19.7%.
Neurocrine Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 28.8184
- Trailing PE
- 61.2514
- PEG
- 1.87
Its diluted EPS in the last 12-months stands at $1.79 per share while it has a forward price to earnings multiple of 28.8184 and a PEG multiple of 1.87. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurocrine Biosciences Inc’s profitability.
Neurocrine Biosciences Inc stock is trading at a EV to sales ratio of 7.7318 and a EV to EBITDA ratio of 98.5064. Its price to sales ratio in the trailing 12-months stood at 8.078.
Neurocrine Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.61 billion
- Total Liabilities
- $582.50 million
- Operating Cash Flow
- $-125900000.00
- Capital Expenditure
- $6.80 million
- Dividend Payout Ratio
- 0%
Neurocrine Biosciences Inc ended 2024 with $2.61 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.61 billion while shareholder equity stood at $1.85 billion.
Neurocrine Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $582.50 million in other current liabilities, 100000.00 in common stock, $-387900000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $160.20 million and cash and short-term investments were $976.70 million. The company’s total short-term debt was $169,700,000 while long-term debt stood at $0.
Neurocrine Biosciences Inc’s total current assets stands at $1.50 billion while long-term investments were $342.60 million and short-term investments were $816.50 million. Its net receivables were $387.60 million compared to accounts payable of $391.60 million and inventory worth $31.70 million.
In 2024, Neurocrine Biosciences Inc's operating cash flow was $-125900000.00 while its capital expenditure stood at $6.80 million.
Comparatively, Neurocrine Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $117.1
- 52-Week High
- $129.29
- 52-Week Low
- $89.04
- Analyst Target Price
- $124.35
Neurocrine Biosciences Inc stock is currently trading at $117.1 per share. It touched a 52-week high of $129.29 and a 52-week low of $129.29. Analysts tracking the stock have a 12-month average target price of $124.35.
Its 50-day moving average was $103.08 and 200-day moving average was $104 The short ratio stood at 2.46 indicating a short percent outstanding of 0%.
Around 105.9% of the company’s stock are held by insiders while 9637.8% are held by institutions.
Frequently Asked Questions About Neurocrine Biosciences Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company’s commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson’s disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company’s products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ” Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.